Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients

Inclusion Criteria: * Patients in whom Candida species have been isolated from blood culture. * Patients accompanied by systemic infectious symptoms during the period from 24 hours (h) before collection of blood culture showing a positive result. * Patients aged 20 years or older on the date of registration. * Patients who have not received systemic administration of antifungal agents or who have started such administration within 48 h. * Patients in whom a central venous (CV) catheter has been removed during the period from 24 h before collection of blood culture showing a positive result to registration, or a CV catheter can be removed within 72 h after registration. * Patients with no verified undrainable abscess with a diameter of at least 3 cm, or impassable occlusive lesions, which are possibly attributable to Candida species. * Patients from whom written informed consent to participate in this study has been obtained (or from their legally acceptable representatives). * Patients who have adequate neutrophil count and hepatic/renal function in the blood test performed within 72 h before registration. Exclusion Criteria: * Patients with a history of adverse reactions associated with fluconazole or micafungin. * Patients who have been treated with fluconazole or micafungin for at least 1 week within 12 weeks. * Patients with a history of detection of fluconazole non-susceptible Candida species within 12 weeks. * Patients in whom the neutrophil count is predicted to dec…